Laboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50161 Kaunas, Lithuania.
Laboratory of Molecular Neurobiology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT-50161 Kaunas, Lithuania.
Int J Mol Sci. 2020 Oct 27;21(21):7962. doi: 10.3390/ijms21217962.
Recently long non-coding RNAs (lncRNAs) were highlighted for their regulatory role in tumor biology. The novel human lncRNA cancer susceptibility candidate 2 () has been characterized as a potential tumor suppressor in several tumor types. However, the roles of and its interplay with in different malignancy grade patient gliomas remain unexplored. Here we screened 99 different malignancy grade astrocytomas for , and gene expression by real-time quantitative polymerase chain reaction (RT-qPCR) in isocitrate dehydrogenase 1 () and O-6-methylguanine methyltransferase () assessed gliomas. expression was significantly downregulated in glioblastomas ( = 0.0003). Gliomas with low expression exhibited a high level of , which was highly associated with the higher glioma grade ( = 0.0001), gliomas ( < 0.0001), and poor patient survival ( < 0.001). Taken together, these observations suggest that acts as a tumor suppressor and potentially as a competing endogenous RNA (ceRNA) for plays important role in glioma pathogenesis and patients' outcomes.
最近，长非编码 RNA（lncRNAs）因其在肿瘤生物学中的调节作用而受到关注。新型人类 lncRNA 癌症易感性候选基因 2（）已被表征为几种肿瘤类型中的潜在肿瘤抑制因子。然而，在不同恶性程度的患者胶质瘤中，的作用及其与的相互作用仍未得到探索。在这里，我们通过实时定量聚合酶链反应（RT-qPCR）筛选了 99 种不同恶性程度的星形细胞瘤中的和基因表达，评估了异柠檬酸脱氢酶 1（）和 O-6-甲基鸟嘌呤甲基转移酶（）的胶质瘤。在胶质母细胞瘤中，表达显著下调（=0.0003）。表达水平低的胶质瘤表现出高水平的，这与较高的胶质瘤分级（=0.0001）、间变性胶质瘤（<0.0001）和患者生存不良（<0.001）高度相关。综上所述，这些观察结果表明，作为一种肿瘤抑制因子，可能作为竞争性内源 RNA（ceRNA），在胶质瘤发病机制和患者预后中发挥重要作用。
